<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03684824</url>
  </required_header>
  <id_info>
    <org_study_id>39</org_study_id>
    <nct_id>NCT03684824</nct_id>
  </id_info>
  <brief_title>Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment</brief_title>
  <official_title>Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      After detailed history and examination, long luteal protocol will be used for controlled&#xD;
      ovarian hyperstimulation, so the patient will start treatment in day 21 of previous cycle,&#xD;
      then in the early follicular phase of next cycle day 2-3 will have transvaginal sonography&#xD;
      for assessment of total ovarian volume and number of antral follicles measuring (2-10mm) in&#xD;
      diameter. On the same day a venous sample will be obtained for the measurement of AMH, basal&#xD;
      FSH and E2 levels&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After detailed history and examination,A transvaginal ultrasound will be done using a&#xD;
      transvaginal transducer with 7.5 MHz.&#xD;
&#xD;
      Each ovary will be measured in 3 planes maximal longitudinal, antero-posterior and transverse&#xD;
      diameters, D1, D2 and D3 respectively. And ovarian volume will be calculated using the&#xD;
      ellipsoid formula:&#xD;
&#xD;
      V = D1× D2 × D3 × 0.523 The volume of both ovaries will be added for the total basal ovarian&#xD;
      volume (BOV).&#xD;
&#xD;
      The mean diameter of the antral follicles will be used by measuring the diameter of the&#xD;
      follicle in two perpendicular directions.&#xD;
&#xD;
      The total AFC is calculated by counting the follicles with mean diameter 2-10mm in both&#xD;
      ovaries.&#xD;
&#xD;
      • Ovulation induction protocol:- Long luteal phase agonist protocol will be used in all&#xD;
      patients. Pituitary suppression will be done using daily subcutaneous injection of&#xD;
      triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the&#xD;
      previous cycle.&#xD;
&#xD;
      Controlled ovarian hyperstimulation will be done using daily intramuscular injection of&#xD;
      highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland),&#xD;
      starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to&#xD;
      patient response.&#xD;
&#xD;
      Induction of oocyte maturation will be done using human chorionic gonadotrophins as an&#xD;
      intramuscular injection of 10000 IU hCG (Choriomon 5000 i.u, IBSA, Switzerland). When there&#xD;
      was sufficient ovarian response that defined as the presence of three or more ovarian&#xD;
      follicles with mean diameter 18mm or more. [15]&#xD;
&#xD;
      • Monitoring of the cycle: The response to ovarian stimulation will be monitored by serial&#xD;
      transvaginal ultrasound starting on day 6 of stimulation and onwards assessing the ovarian&#xD;
      follicles number and diameter, as well as serum E2 level as indicated.&#xD;
&#xD;
      • Oocyte Retriveal: Oocyte retrieval will done (34-36 hours) after hCG injection, by&#xD;
      transvaginal guided vacuumed oocyte aspiration using double lumen oocyte aspiration needle&#xD;
      for flushing of the follicles.&#xD;
&#xD;
      • Measurement of FSH and E2 Levels: A blood sample will be withdrawn on day (2 - 3) of the&#xD;
      menstrual cycle in which the patient will undergo stimulation, for estimation the basal FSH&#xD;
      (mIU/ml) , E2 (pg/ml) and AMH (ng/ml) levels.&#xD;
&#xD;
      Both FSH and E2 will be tested using VIDAS equipment, both the FSH and E2 were measured by&#xD;
      automated quantitative testing, using the ELFA technique (Enzyme Linked Fluorescent Assay).&#xD;
      In the same way, AMH will be tested by Beckman Coulter, using GenII ELISA, USA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">September 2018</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of retrieved oocytes</measure>
    <time_frame>34 hours after HCG triggering of ovulation</time_frame>
    <description>number of oocytes retrieved at day of ovum pick up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>14 days after embryo transfer</time_frame>
    <description>Ultrasound detection of intrauterine gestational sac</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Invitro Fertilization</condition>
  <arm_group>
    <arm_group_label>obese group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>100 obese patients with BMI between 30 and 35 who are undergoing IVF/ICSI treatment for infertility</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Long luteal phase GnRH agonist protocol</intervention_name>
    <description>Pituitary suppression will be done using daily subcutaneous injection of triptorelin acetate ( Decapeptyl 0.1mg, Ferring, Germany). Starting from day 21 of the previous cycle</description>
    <arm_group_label>obese group</arm_group_label>
    <other_name>Decapeptyl 0.1mg amp</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropins</intervention_name>
    <description>Controlled ovarian hyperstimulation will be done using daily intramuscular injection of highly purified Human Menopausal Gonadotrophins (Merional 75 IU/ml, IBSA, Switzerland), starting from day 2-3 of the stimulated cycle, total dose will be adjusted according to patient response</description>
    <arm_group_label>obese group</arm_group_label>
    <other_name>Merional 75 IU/ml, IBSA, Switzerland</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Women between 20 and 35 age.&#xD;
&#xD;
          -  BMI: 30 -35&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women less than 19 years or more than 35 years.&#xD;
&#xD;
          -  BMI less than 30 or more than 35&#xD;
&#xD;
          -  Women with Hypothyroidism.&#xD;
&#xD;
          -  Women receiving any treatment may reduce their fertility e.g: chemotherapy.&#xD;
&#xD;
          -  Women with recurrent IVF failure&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed maged</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed maged, MD</last_name>
    <phone>+2001005227404</phone>
    <email>prof.ahmedmaged@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ameer Elsherief, MD</last_name>
    <email>ameerelsherief@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ameer Elsherief</name>
      <address>
        <city>Minya</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Ahmed Maged, MD</last_name>
      <phone>01005227404</phone>
      <email>prof.ahmedmaged@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Ameer elsherief, MD</last_name>
      <phone>00201001204427</phone>
      <email>ameerelsherief@yahoo.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 19, 2018</study_first_submitted>
  <study_first_submitted_qc>September 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 26, 2018</study_first_posted>
  <last_update_submitted>September 24, 2018</last_update_submitted>
  <last_update_submitted_qc>September 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Maged</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

